The clinical challenges of lifetime HAART

A Decade of HAART: The Development and Global Impact of Highly Active Antiretroviral Therapy

Volumn , Issue , 2009, Pages

  Paredes, Roger ^a   Sherer, Renslow ^b   Clotet, Bonaventura ^c  

^a Partners AIDS Research Center   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Highly active antiretroviral therapy; HIV AIDS; Long term ART; Treatment

Indexed keywords

EID: 84921556072     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780199225859.003.0026     Document Type: Chapter

References (322)

1. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. (2006). The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 20:2371-9.
2. Santos Corraliza E, Fuertes Martin A. (2006). Side effects of antiretroviral therapy. Fisiopathology, clinical manifestations and treatment. An Med Interna 23:338-44.
3. UNAIDS. (2006). Report on the global AIDS epidemic 2006. Geneva: UNAIDS. Available at.
4. Mocroft A, Ledergerber B, Katlama C, et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362:22-9.
5. Palella FJ Jr, Baker RK, Moorman AC, et al. (2006). Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43:27-34.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-60.
7. Parsons TD, Braaten AJ, Hall CD, Robertson KR. (2006). Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 4:11.
8. Gibbie T, Mijch A, Ellen S, et al. (2006). Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med 7:112-21.
9. Ostrowski MA, Krakauer DC, Li Y, et al. (1998). Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 72:7772-84.
10. Cohen OJ, Kinter A, Fauci AS. (1997). Host factors in the pathogenesis of HIV disease. Immunol Rev 159:31-48.
11. Pantaleo G, Fauci AS. (1996). Immunopathogenesis of HIV infection. Annu Rev Microbiol 50:825-54.
12. Fauci AS. (1996). Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-34.
13. Fauci AS. (1996). Host factors in the pathogenesis of HIV disease. Antibiot Chemother 48:4-12.
14. Rosenberg ZF, Fauci AS. (1990). Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. Immunol Today 11:176-80.
15. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z. (2006). Cellular co-factors of HIV-1 integration. Trends Biochem Sci 31:98-105.
16. Lewinski MK, Yamashita M, Emerman M, et al. (2006). Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2(6):e60.
17. Chiu TK, Davies DR. (2004). Structure and function of HIV-1 integrase. Curr Top Med Chem 4:965-77.
18. Brin E, Yi J, Skalka AM, Leis J. (2000). Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration. J Biol Chem 275:39287-95.
19. Hindmarsh P, Leis J. (1999). Retroviral DNA integration. Microbiol Mol Biol Rev 63:836-43.
20. Asante-Appiah E, Skalka AM. (1997). Molecular mechanisms in retrovirus DNA integration. Antiviral Res 36:139-56.
21. Vink C, Plasterk RH. (1993). The human immunodeficiency virus integrase protein. Trends Genet 9:433-8.
22. Sakai H, Kawamura M, Sakuragi J, et al. (1993). Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 67:1169-74.
23. Cristina J. (2005). Genetic diversity and evolution of hepatitis C virus in the Latin American region. J Clin Virol 34 (Suppl 2):S1-7.
24. Gonzalez-Lopez C, Gomez-Mariano G, Escarmis C, Domingo E. (2005). Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol 5:366-74.
25. Jerzak G, Bernard KA, Kramer LD, Ebel GD. (2005). Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 86:2175-83.
26. Coffin JM. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-9.
27. Smith DB, McAllister J, Casino C, Simmonds P. (1997). Virus 'quasispecies': making a mountain out of a molehill? J Gen Virol 78:1511-9.
28. Chun T-W, Nickle DC, Justement JS, et al. (2005). HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115:3250-5.
29. Nunnari G, Sullivan J, Xu Y, et al. (2005). HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 21:714-8.
30. Chun TW, Nickle DC, Justement JS, et al. (2005). HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115:3250-5.
31. Siliciano JD, Siliciano RF. (2004). A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 54:6-9.
32. Siliciano JD, Kajdas J, Finzi D, et al. (2003). Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-8.
33. Lambotte O, Deiva K, Tardieu M. (2003). HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 13:95-103.
34. Finzi D, Blankson J, Siliciano JD, et al. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-7.
35. Siliciano RF. (1998). A reservoir for HIV in patients on combination antiretroviral therapy. Hopkins HIV Rep 10:1, 5-6, 11.
36. Schrager LK, D'Souza MP. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71.
37. Finzi D, Hermankova M, Pierson T, et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-300.
38. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100:4144-9.
39. Frost SD, Liu Y, Pond SL, et al. (2005). Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 79:6523-7.
40. El-Sadr WM, Lundgren JD, Neaton JD, et al. (2006). CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283-96.
41. Lawrence J, Mayers DL, Hullsiek KH, et al. (2003). Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349:837-46.
42. Ruiz L, Ribera E, Bonjoch A, et al. (2003). Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 188:977-85.
43. Ruiz L, Paredes R, Gómez G, et al. (2007). Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 21:169-78.
44. Weber R, Sabin CA, Friis-Moller N, et al. (2006). Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166:1632-41.
45. Soriano V, Barreiro P, Nunez M. (2006). Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 57:815-8.
46. Rockstroh JK. (2006). Management of hepatitis C/HIV coinfection. Curr Opin Infect Dis 9:8-13.
47. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. (2006). Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20:49-57.
48. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. (2006). Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 145:397-406.
49. Valcour V, Paul R. (2006). HIV infection and dementia in older adults. Clin Infect Dis 42:1449-54.
50. Ghafouri M, Amini S, Khalili K, Sawaya BE. (2006). HIV-1 associated dementia: symptoms and causes. Retrovirology 3:28.
51. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. (2006). Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol (Berl) 111:529-38.
52. Fischer-Smith T, Rappaport J. (2005). Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med 7:1-26.
53. Goodkin K, Wilkie FL, Concha M, et al. (2001). Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 54(Suppl 1):S35-43.
54. Gilden D. (1996). When HAART is not enough. GMHC Treat Issues 10(10):1-6.
55. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341:1865-73.
56. Montaner JS, Reiss P, Cooper D, et al. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279:930-7.
57. D'Aquila RT, Hughes MD, Johnson VA, et al. (1996). Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 124:1019-30.
58. Staszewski S, Keiser P, Montaner J, et al. (2001). Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285:1155-63.
59. Gulick RM, Ribaudo HJ, Shikuma CM, et al. (2004). Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350:1850-61.
60. Hammer SM, Saag MS, Schechter M, et al. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 14:827-43.
61. DHHS. (2006). DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. Available at.
62. Bryan CS. (1996). Hit early, hit hard: new strategies for HIV. J S C Med Assoc 92:361-3.
63. Lange J. (1995). Combination antiretroviral therapy. Back to the future. Drugs 49(Suppl 1): 32-7; discussion 8-40.
64. Ho DD. (1995). Time to hit HIV, early and hard. N Engl J Med 333:450-1.
65. Izopet J, Salama G, Pasquier C, et al. (1998). Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 19:478-83.
66. Richman DD, Morton SC, Wrin T, et al. (2004). The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-401.
67. Ait-Khaled M, Rakik A, Griffin P, et al. (2003). HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther 8:111-20.
68. Naugler WE, Yong FH, Carey VJ, Dragavon JA, Coombs RW, Frenkel LM. (2002). T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytiuminducing phenotype are associated with CD4 cell depletion during didanosine therapy. J Infect Dis 185:448-55.
69. Miller MD, Margot NA, Lamy PD, et al. (2002). Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr 27:450-8.
70. Dronda F, Casado JL, Moreno S, et al. (2001). Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 17:211-5.
71. Hertogs K, Bloor S, Kemp SD, et al. (2000). Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:1203-10.
72. Havlir DV, Hellmann NS, Petropoulos CJ, et al. (2000). Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283:229-34.
73. Harrigan PR, Hertogs K, Verbiest W, et al. (1999). Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 13:1863-71.
74. Patick AK, Duran M, Cao Y, et al. (1998). Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42:2637-44.
75. Nijhuis M, Schuurman R, de Jong D, et al. (1997). Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 176:398-405.
76. Kuritzkes DR, Quinn JB, Benoit SL, et al. (1996). Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-81.
77. Negredo E, Ribalta J, Paredes R, et al. (2002). Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16:1383-9.
78. Hirsch HH, Battegay M. (2002). Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection 30:293-8.
79. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. (2002). Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 162:2621-8.
80. Fellay J, Boubaker K, Ledergerber B, et al. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358:1322-7.
81. Doser N, Sudre P, Telenti A, et al. (2001). Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defic Syndr 26:389-90.
82. Tebas P, Powderly WG, Claxton S, et al. (2000). Accelerated bone mineral loss in HIVinfected patients receiving potent antiretroviral therapy. AIDS 14:F63-7.
83. Sighinolfi L, Carradori S, Ghinelli F. (2000). Avascular necrosis of the femoral head: a side effect of highly active antiretroviral therapy (HAART) in HIV patients? Infection 28:254-5.
84. Carr A, Samaras K, Chisholm DJ, Cooper DA. (1998). Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351:1881-3.
85. Harrington M, Carpenter CC. (2000). Hit HIV-1 hard, but only when necessary. Lancet 355:2147-52.
86. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. (2003). Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 138:620-6.
87. Madruga JV, Cahn P, Grinsztejn B, et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38.
88. Lazzarin A, Campbell T, Clotet B, et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48.
89. Madruga JV, Berger D, McMurchie M, et al. (2007). Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:49-58.
90. Clotet B, Bellos N, Molina JM, et al. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-78.
91. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrugresistant virus: a phase II randomised controlled trial. Lancet 369:1261-9.
92. Wall Street Journal, 22 January 1997. pC1.
93. Carrieri MP, Leport C, Protopopescu C, et al. (2006). Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 41:477-85.
94. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. (2006). Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 3:CD001442.
95. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. (2004). Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 36:808-16.
96. Bartlett JA, Fath MJ, Demasi R, et al. (2006). An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20:2051-64.
97. Altice FL, Mostashari F, Friedland GH. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 28:47-58.
98. Cheever LW, Wu AW. (1999). Medication Adherence Among HIV-Infected Patients: Understanding the Complex Behavior of Patients Taking This Complex Therapy. Curr Infect Dis Rep 1:401-7.
99. Gebo KA, Keruly J, Moore RD. (2003). Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med 18:104-11. 100.
100. Gellaitry G, Cooper V, Davis C, Fisher M, Date HL, Horne R. (2005). Patients' perception of information about HAART: impact on treatment decisions. AIDS Care 17:367-76.
101. Holmes WC, Pace JL. (2002). HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence. J Gen Intern Med 17:677-83.
102. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. (2004). Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 15:38-44.
103. Kemppainen JK, Levine RE, Mistal M, Schmidgall D. (2001). HAART adherence in culturally diverse patients with HIV/AIDS: a study of male patients from a Veteran's Administration Hospital in northern California. AIDS Patient Care STDS 15:117-27.
104. Nachega JB, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, Karstaedt AS. (2005). HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South Africa. J Acquir Immune Defic Syndr 38:196-201.
105. Parsons SK, Cruise PL, Davenport WM, Jones V. (2006). Religious beliefs, practices and treatment adherence among individuals with HIV in the southern United States. AIDS Patient Care STDS 20:97-111.
106. Reynolds NR, Testa MA, Marc LG, et al. (2004). Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 8:141-50.
107. Roberts KJ. (2000). Physician beliefs about antiretroviral adherence communication. AIDS Patient Care STDS 14:477-84.
108. Roberts KJ. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care STDS 14:155-68.
109. Roberts KJ, Mann T. (2000). Barriers to antiretroviral medication adherence in HIVinfected women. AIDS Care 12:377-86.
110. Locadia M, van Grieken RA, Prins JM, de Vries HJ, Sprangers MA, Nieuwkerk PT. (2006). Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection. Antivir Ther 11:335-41.
111. Yasuda JM, Miller C, Currier JS, et al. (2004). The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther 9:753-61.
112. Beach MC, Keruly J, Moore RD. (2006). Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med 21:661-5.
113. Boarts JM, Sledjeski EM, Bogart LM, Delahanty DL. (2006). The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav 10:253-61.
114. Ironson G, O'Cleirigh C, Fletcher MA, et al. (2005). Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med 67:1013-21.
115. Taiwo BO. (2006). Nevirapine toxicity. Int J STD AIDS 17:364-9; quiz 70.
116. Hitti J, Frenkel LM, Stek AM, et al. (2004). Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 36:772-6.
117. Law WP, Dore GJ, Duncombe CJ, et al. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17:2191-9.
118. Rotger M, Csajka C, Telenti A. (2006). Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep 3:118-25.
119. Motsinger AA, Ritchie MD, Shafer RW, et al. (2006). Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics 16:837-45.
120. Martin AM, Nolan D, Mallal S. (2005). HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 65:571-4.
121. Martin AM, Nolan D, Gaudieri S, et al. (2004). Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 101:4180-5.
122. Mallal S, Nolan D, Witt C, et al. (2002). Association between presence of HLAB* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-32.
123. Grinspoon S, Carr A. (2005). Cardiovascular risk and body-fat abnormalities in HIVinfected adults. N Engl J Med 352:48-62.
124. Milinkovic A, Martinez E. (2005). Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother 56:6-9.
125. Kotler DP. (2003). HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis. AIDS Read 13(4 Suppl):S5-9.
126. Grinspoon SK. (2005). Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 118 (Suppl 2):23S-8S.
127. Hammer SM, Saag MS, Schechter M, et al. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-43.
128. Negredo E, Molto J, Burger D, et al. (2005). Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 38:47-52.
129. Maggiolo F, Ripamonti D, Suter F. (2005). Switch strategies in patients on effective HAART. J Antimicrob Chemother 55:821-3.
130. Carr A, Workman C, Smith DE, et al. (2002). Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288:207-15.
131. Nolan D, Mallal S. (2003). Thymidine analogue-sparing highly active antiretroviral therapy (HAART). J HIV Ther 8:2-6.
132. Ruiz L, Negredo E, Domingo P, et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 27:229-36.
133. Gavrila A, Hsu W, Tsiodras S, et al. (2005). Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 40:745-9.
134. Calmy A, Hirschel B, Hans D, Karsegard VL, Meier CA. (2003). Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 17:770-2.
135. Mori A, Lo Russo G, Agostini T, Pattarino J, Vichi F, Dini M. (2006). Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg 59:1209-16.
136. Mest DR, Humble G. (2006). Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 32:1336-45.
137. Engelhard P. (2006). Correction options for lipoatrophy in HIV-infected patients. AIDS Patient Care STDS 20:151-60.
138. Guaraldi G, Orlando G, De Fazio D, et al. (2005). Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 10:753-9.
139. Guaraldi G, De Fazio D, Orlando G, et al. (2005). Facial lipohypertrophy in HIVinfected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis 40(2):e13-5.
140. Burnouf M, Buffet M, Schwarzinger M, et al. (2005). Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. Arch Dermatol 141:1220-4.
141. Serra-Renom JM, Fontdevila J. (2004). Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg 114(2):551-5; discussion 6-7.
142. Talmor M, Hoffman LA, LaTrenta GS. (2002). Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg 49(1):11-7; discussion 117-8.
143. Burgess E, Wanke C. (2005). Use of recombinant human growth hormone in HIVassociated lipodystrophy. Curr Opin Infect Dis 18:17-24.
144. Luzi L, Meneghini E, Oggionni S, Tambussi G, Piceni-Sereni L, Lazzarin A. (2005). GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. Eur J Endocrinol 153:781-9.
145. Grinspoon S. (2003). Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 37(Suppl 2):S85-90.
146. Sutinen J, Kannisto K, Korsheninnikova E, et al. (2004). Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapyassociated lipodystrophy. Am J Physiol Endocrinol Metab 286(6):E941-9.
147. Sutinen J, Hakkinen AM, Westerbacka J, et al. (2003). Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 8:199-207.
148. Wohl DA. (2004). Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies. Top HIV Med 12:89-93.
149. Mulligan K, Yang Y, Koletar S, et al. (2006). Effects of Metformin and Rosiglitazone on Body Composition in HIV-infected Patients with Hyperinsulinemia and Elevated Waist/Hip Ratio: A Randomized, Placebo-controlled Trial. 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February, 2006, Denver, CO, USA. [Abstract 147].
150. Shikuma C, Parker R, Sattler F, et al. Effects of Physiologic Testosterone Supplementation on Fat Mass and Distribution in HIV-infected Men with Abdominal Obesity: ACTG 5079. 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver, CO, USA. [Abstract 149].
151. Jemsek JG, Arathoon E, Arlotti M, et al. (2006). Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviralnaive HIV-infected patients. Clin Infect Dis 42:273-80.
152. Haerter G, Manfras BJ, Mueller M, Kern P, Trein A. (2004). Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 18:952-5.
153. Calza L, Manfredi R, Chiodo F. (2003). Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 22:89-99.
154. Young J, Weber R, Rickenbach M, et al. (2005). Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 10:585-91.
155. Crane HM, Van Rompaey SE, Kitahata MM. (2006). Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20:1019-26.
156. Thiebaut R, El-Sadr WM, Friis-Moller N, et al. (2005). Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 10:811-23.
157. Pan G, Yang Z, Ballinger SW, McDonald JM. (2006). Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci 1068:297-308.
158. Curtis JR, Smith B, Weaver M, et al. (2006). Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Res Hum Retroviruse 22:125-31.
159. Bongiovanni M, Fausto A, Cicconi P, et al. (2005). Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr 40:503-4.
160. Martin K, Lawson-Ayayi S, Miremont-Salame G, et al. (2004). Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med 5:421-6.
161. Brown TT, Ruppe MD, Kassner R, et al. (2004). Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 89:1200-6.
162. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. (2004). Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Meta 89:24-8.
163. Teichmann J, Stephan E, Lange U, et al. (2003). Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infec 46:221-7.
164. Loiseau-Peres S, Delaunay C, Poupon S, et al. (2002). Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine 69:482-5.
165. Borderi M, Farneti B, Tampellini L, et al. (2002). HIV-1, HAART and bone metabolism. New Microbiol 25:375-84.
166. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. (2001). Osteopenia in HIVinfected patients: is it the disease or is it the treatment? AIDS 15:807-8.
167. Johnson M, Grinsztejn B, Rodriguez C, et al. (2006). 96-week comparison of oncedaily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20:711-8.
168. Noor MA, Flint OP, Maa JF, Parker RA. (2006). Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20:1813-21.
169. Yan Q, Hruz PW. (2005). Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40:398-403.
170. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. (2005). In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispo 33:1729-39.
171. De Luca A, Cozzi-Lepri A, Antinori A, et al. (2006). Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir The 11:609-18.
172. van Leth F, Phanuphak P, Stroes E, et al. (2004). Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1(1):e19.
173. Clotet B, van der Valk M, Negredo E, Reiss P. (2003). Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 34(Suppl 1):S79-84.
174. Tebas P, Yarasheski K, Henry K, et al. (2004). Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20:589-94.
175. Negredo E, Cruz L, Paredes R, et al. (2002). Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 34:504-10.
176. Martinez E, Garcia-Viejo MA, Blanco JL, et al. (2000). Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 31:1266-73.
177. Estrada V, De Villar NG, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. (2002). Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 35:69-76.
178. Ward DJ, Curtin JM. (2006). Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 20:542-8.
179. Sax PE. (2006). Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 18:149-57.
180. Venter JC, Adams MD, Myers EW, et al. (2001). The sequence of the human genome. Science 291:1304-51.
181. Rotger M, Colombo S, Cavassini M, et al. (2006). Genetic Variability of CYP2B6 in Individuals with Extremely High Efavirenz Plasma Concentrations. 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006; Denver, CO, USA. [Abstract 572].
182. Friis-Moller N, Sabin CA, Weber R, et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003.
183. Saves M, Chene G, Ducimetiere P, et al. (2003). Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37:292-8.
184. Bergersen BM. (2006). Cardiovascular Risk in Patients with HIV Infection: Impact of Antiretroviral Therapy. Drugs 66:1971-87.
185. Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006). Exposure to PI and NNRTI and risk of myocardial infarction: Results from the D:A:D study. 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver, CO, USA. [Abstract 144].
186. Castillo R, Pedalino RP, El-Sherif N, Turitto G. (2002). Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia. Ann Pharmacother 36:1006-8.
187. Ogedegbe AE, Thomas DL, Diehl AM. (2003). Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 3:329-37.
188. Walker UA, Setzer B, Venhoff N. (2002). Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16:2165-73.
189. Karras A, Lafaurie M, Furco A, et al. (2003). Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36:1070-3.
190. Izzedine H, Hulot JS, Vittecoq D, et al. (2005). Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a doubleblind randomized active-controlled multicentre study. Nephrol Dial Transplant 20:743-6.
191. Antoniou T, Raboud J, Chirhin S, et al. (2005). Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 6:284-90.
192. Coca S, Perazella MA. (2002). Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 324:342-4.
193. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. (2003). Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 17:935-7.
194. Gallant JE, Parish MA, Keruly JC, Moore RD. (2005). Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40:1194-8.
195. Jones R, Stebbing J, Nelson M, et al. (2004). Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 7:1489-95.
196. Mauss S, Berger F, Schmutz G. (2005). Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19:93-5.
197. Peyriere H, Reynes J, Rouanet I, et al. (2004). Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Synd 35:269-73.
198. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. (2003). Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 37(12):e174-6.
199. Verhelst D, Monge M, Meynard JL, et al. (2002). Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40:1331-3.
200. Winston A, Amin J, Mallon P, et al. (2006). Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7:105-11.
201. Gallant JE, Staszewski S, Pozniak AL, et al. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
202. Izzedine H, Hulot JS, Villard E, et al. (2006). Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. J Infect Dis 194:1481-91.
203. Nowak MA. (1992). Variability of HIV infections. J Theor Biol 155:1-20.
204. Nowak MA, Bonhoeffer S, Shaw GM, May RM. (1997). Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 184:203-17.
205. Ho DDN, Avidan U, Perelson AS, Chen W, Leonard JM, Markowitz M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-6.
206. Nei M, Jin L. (1989). Variances of the average numbers of nucleotide substitutions within and between populations. Mol Biol Evol 6:290-300.
207. Ji J, Loeb LA. (1994). Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene. Virology 199:323-30.
208. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ. (2006). Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80:2472-82.
209. Kijak GH, McCutchan FE. (2005). HIV diversity, molecular epidemiology, and the role of recombination. Curr Infect Dis Rep 7:480-8.
210. Rambaut A, Posada D, Crandall KA, Holmes EC. (2004). The causes and consequences of HIV evolution. Nat Rev Genet 5:52-61.
211. Kalish ML, Robbins KE, Pieniazek D, et al. (2004). Recombinant viruses and early global HIV-1 epidemic. Emerg Infect Dis 10:1227-34.
212. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. (1995). Recombination in HIV-1. Nature 374:124-6.
213. Robertson DL, Hahn BH, Sharp PM. (1995). Recombination in AIDS viruses. J Mol Evol 40:249-59.
214. Marcello A. (2006). Latency: the hidden HIV-1 challenge. Retrovirology 3:7.
215. Kulkosky J, Bray S. (2006). HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res 4:199-208.
216. Saksena NK, Potter SJ. (2003). Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 5:3-18.
217. Pierson T, McArthur J, Siliciano RF. (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immuno 18:665-708.
218. Chun TW, Carruth L, Finzi D, et al. (1997). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-8.
219. Rouzine IM, Rodrigo A, Coffin JM. (2001). Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev 65:151-85.
220. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. (2000). Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74:6262-8.
221. D'Amato RM, D'Aquila RT, Wein LM. (1998). Management of antiretroviral therapy for HIV infection: modelling when to change therapy. Antivir Ther 3:147-58.
222. Calderon EJ, Torres Y, Medrano FJ, et al. (1995). Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. Eur J Clin Microbiol Infect Dis 14:512-9.
223. Larder BA. (1994). Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 75(Pt 5):951-7.
224. Boucher CA, Cammack N, Schipper P, et al. (1993). High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37:2231-4.
225. Boucher CA, O'Sullivan E, Mulder JW, et al. (1992). Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency viruspositive subjects. J Infect Dis 165:105-10.
226. St Clair MH, Martin JL, Tudor-Williams G, et al. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-9.
227. Larder BA, Darby G, Richman DD. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-4.
228. Johnson VA, Brun-Vezinet F, Clotet B, et al. (2006). Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14:125-30.
229. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. (2004). Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9:829-48.
230. Hogg RS, Bangsberg DR, Lima VD, et al. (2006). Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART. PLoS Med 3(9):356.
231. Quinones-Mateu ME, Arts EJ. (2002). Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 5:224-33.
232. Wainberg MA, Gu Z, Montaner JS, et al. (1995). Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-7.
233. Gao Q, Gu Z, Parniak MA, et al. (1993). The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 37:1390-2.
234. Wakefield JK, Jablonski SA, Morrow CD. (1992). In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol 66:6806-12.
235. Wainberg MA. (2004). The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2:147-51.
236. Deval J, White KL, Miller MD, et al. (2004). Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 279:509-16.
237. Perno CF, Cenci A, Piro C, et al. (2003). HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment. Scand J Infect Dis Suppl 35(Suppl 106):37-40.
238. Van Rompay KK, Matthews TB, Higgins J, et al. (2002). Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol 76:6083-92. 239.
239. Devereux HL, Emery VC, Johnson MA, Loveday C. (2001). Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65:218-24.
240. Sharma PL, Crumpacker CS. (1999). Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudineselected Met184Val. J Virol 73:8448-56.
241. Phillips AN, McLean AR, Loveday C, et al. (1999). In vivo HIV-1 replicative capacity in early and advanced infection. AIDS 13:67-73.
242. Feng JY, Anderson KS. (1999). Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistr 38:9440-8.
243. Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA. (1998). Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 14:735-40.
244. Back NK, Nijhuis M, Keulen W, et al. (1996). Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. Embo J 15:4040-9.
245. Quan Y, Gu Z, Li X, Li Z, Morrow CD, Wainberg MA. (1996). Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 70:5642-5.
246. Wainberg MA, Drosopoulos WC, Salomon H, et al. (1996). Enhanced fidelity of 3TCselected mutant HIV-1 reverse transcriptase. Science 271:1282-5.
247. Margot NA, Waters JM, Miller MD. (2006). In Vitro HIV-1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine. Antimicrob Agents Chemother 50:4087-95.
248. Turner D, Brenner B, Wainberg MA. (2003). Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immuno 10:979-81.
249. Miller V, Phillips A, Rottmann C, et al. (1998). Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 177:1521-32.
250. Balzarini J, Karlsson A, Perez-Perez MJ, et al. (1993). HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virolog 192:246-53.
251. Boucher CA, Lange JM, Miedema FF, et al. (1992). HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 6:1259-64.
252. Larder BA, Kellam P, Kemp SD. (1991). Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-44.
253. Tisdale M, Schulze T, Larder BA, Moelling K. (1991). Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol 72(Pt 1):59-66.
254. Larder BA, Kemp SD. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-8.
255. Gu Z, Salomon H, Cherrington JM, et al. (1995). K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 39:1888-91.
256. Winston A, Stebbing J. (2004). The K65R mutation in HIV-1 reverse transcriptase. J HIV Ther 9:25-7.
257. Nikolenko GN, Svarovskaia ES, Delviks KA, Pathak VK. (2004). Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J Virol 78:8761-70.
258. Moyle GJ. (2004). The K65R mutation: selection, frequency, and possible consequences. AIDS Read 14:595-7; 601-3.
259. Garcia-Lerma JG, MacInnes H, Bennett D, et al. (2003). A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 77:5685-93.
260. Roge BT, Katzenstein TL, Obel N, et al. (2003). K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 8:173-82.
261. Shah FS, Curr KA, Hamburgh ME, et al. (2000). Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 275:27037-44.
262. Gu Z, Arts EJ, Parniak MA, Wainberg MA. (1995). Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci USA 28:92(7):2760-4.
263. Gu Z, Fletcher RS, Arts EJ, Wainberg MA, Parniak MA. (1994). The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 269:28118-22.
264. Miller V, Ait-Khaled M, Stone C, et al. (2000). HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14:163-71.
265. Ray AS, Basavapathruni A, Anderson KS. (2002). Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 277:40479-90.
266. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. (2003). Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 17:1889-96.
267. Paredes R, Mocroft A, Kirk O, et al. (2000). Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 160:1123-32.
268. Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, Redfield RR. (2006). Successful Treatment with Atazanavir and Lopinavir/Ritonavir Combination Therapy in Protease Inhibitor-Susceptible and Protease Inhibitor-Resistant HIV-Infected Patients. AIDS Patient Care STDS 20:745-59.
269. Hellinger J, Cohen C, Morris A, et al. (2005). Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. HIV Clin Trials 6:107-17.
270. Deeks SG, Hoh R, Neilands TB, et al. (2005). Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192:1537-44.
271. Castagna A, Danise A, Menzo S, et al. (2006). Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20:795-803.
272. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. (2004). Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 27(Suppl 1):31-9.
273. Burgi A, Brodine S, Wegner S, et al. (2005). Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 104:1505-11.
274. Herida M, Mary-Krause M, Kaphan R, et al. (2003). Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447-53.
275. Engels EA, Pfeiffer RM, Goedert JJ, et al. (2006). Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20:1645-54.
276. Bower M, Palmieri C, Dhillon T. (2006). AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 19:14-9.
277. Boshoff C, Weiss R. (2002). AIDS-related malignancies. Nat Rev Cancer 2:373-82.
278. Appleby P, Beral V, Newton R, Reeves G. (2000). Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823-30.
279. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. (2004). Antitumour effects of antiretroviral therapy. Nat Rev Cancer 4:861-75.
280. Stebbing J, Gazzard B, Mandalia S, et al. (2004). Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 22:2177-83.
281. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. (2000). Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 96:2730-4.
282. Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. (1999). The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 86:2391-7.
283. Sirera G, Videla S, Pinol M, et al. (2006). High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 20:1201-4.
284. Clifford GM, Polesel J, Rickenbach M, et al. (2005). Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425-32.
285. Palefsky JM, Holly EA, Ralston ML, et al. (2001). Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Synd 28:422-8.
286. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. (1998). Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 12:1459-64.
287. Minkoff H, Ahdieh L, Massad LS, et al. (2001). The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 15:2157-64.
288. Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J. (2006). Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 51:1-11.
289. Hentrich M, Maretta L, Chow KU, et al. (2006). Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 17:914-9.
290. Hoffmann C, Chow KU, Wolf E, et al. (2004). Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virusassociated Hodgkin's disease. Br J Haematol 125:455-62.
291. Lopez-Caleya JF, Martin V, Martin L, Perez-Simon R, Carro JA, Alcoba M. (2006). [Prevalence of coinfection by human immunodeficiency virus and hepatitis C virus in the Leon Health Area: 1992-2000]. Enferm Infecc Microbiol Clin 24:365-9.
292. Mohsen AH, Murad S, Easterbrook PJ. (2005). Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 6:206-15.
293. Saiz de la Hoya P, Bedia M, Murcia J, Cebria J, Sanchez-Paya J, Portilla J. (2005). Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison. Enferm Infecc Microbiol Clin 23:53-7.
294. Lewden C, Salmon D, Morlat P, et al. (2005). Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34:121-30.
295. Bica I, McGovern B, Dhar R, et al. (2001). Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32:492-7.
296. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 17:1467-71.
297. Mocroft A, Brettle R, Kirk O, et al. (2002). Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16:1663-71.
298. Rockstroh JK, Mocroft A, Soriano V, et al. (2005). Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192:992-1002.
299. Qurishi N, Kreuzberg C, Luchters G, et al. (2003). Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708-13.
300. Stoff DM, Khalsa JH, Monjan A, Portegies P. (2004). Introduction: HIV/AIDS and Aging. AIDS 18(Suppl 1):S1-2.
301. Smith G. (2005). Statement of Senator Gordon H. Smith. Aging hearing: HIV over fifty, exploring the new threat. Washington DC: United States Congress.
302. Farinpour R, Miller EN, Satz P, et al. (2003). Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS. J Clin Exp Neuropsychol 25:654-70.
303. Rempel HC, Pulliam L. (2005). HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19:127-35.
304. Brew BJ. (2004). Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18(Suppl 1):S75-8.
305. Esiri MM, Biddolph SC, Morris CS. (1998). Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 65:29-33.
306. Kim YS, Joh TH. (2006). Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333-47.
307. Wersinger C, Sidhu A. (2002). Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 1:221-42.
308. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. (2002). Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm 109:399-410.
309. Tanaka M, Endo K, Suzuki T, Kakita A, Takahashi H, Sata T. (2000). Parkinsonism in HIV encephalopathy. Mov Disord 15:1032-3.
310. Mirsattari SM, Power C, Nath A. (1998). Parkinsonism with HIV infection. Mov Disord 13:684-9.
311. Sui Z, Sniderhan LF, Fan S, et al. (2006). Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci 23:2623-34.
312. Rumbaugh J, Turchan-Cholewo J, Galey D, et al. (2006). Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism. Faseb J 20:1736-8.
313. Daily A, Nath A, Hersh LB. (2006). Tat peptides inhibit neprilysin. J Neurovirol 12:153-60.
314. Avraham HK, Jiang S, Lee TH, Prakash O, Avraham S. (2004). HIV-1 Tat-mediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J Immuno 173:6228-33.
315. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM. (2006). HIVassociated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 43:1198-205.
316. Sachs J. (2005). The End of Poverty. New York: Penguin Press.
317. Kaiser Family Foundation. (2006). ADAP Update, 2006. Available at accessed 9.11.07).
318. Egger M. (2007). Outcomes of ART in Resource-Limited and Industrialized Countries. 14th Conference on Retroviruses and Opportunistic Infections (CROI), 23-28 February 2007, Los Angeles, CA, USA. [Abstract #62].
319. UNAIDS. (2006). Report on the Global AIDS Epidemic, 2006. Geneva: UNAIDS.
320. Getahun R. (2007). Progress in the Global STOP-TB Program. International AIDS Society Conference, 23-25 July 2007, Sydney, Australia. [Abstract TuSy101].
321. HolguÌn A, Ramirez de Arellano E, Rivas P, Soriano V. (2006). Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 8:98-107.
322. Geretti AM. (2006). HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19:1-7.